HeartWare Adds Synergy Circulatory Support System With $30 Mil. CircuLite Buy
This article was originally published in The Gray Sheet
Executive Summary
The acquisition could significantly expand the targeted market base for HeartWare, but first the company will need to re-launch CircuLite’s Synergy in Europe, which experiences a design problem the first time around.
You may also be interested in...
European Markets Show Pockets Of Strong Growth For Cardiovascular Devices
The big five European Union markets – Germany, France, the UK, Spain, and Italy – are expected to see strong growth in some of the more common cardiovascular device implant procedures over the next four years, with ventricular assist device (VAD) implantations topping the list. All five major EU markets are forecast to experience healthy mid-teen compound annual growth rates in VAD implantation volume, according to recently published European procedure volume reports from Medtech Insight.
Tug Of War In The LVAD Market
With the rivalry between Thoratec and HeartWare intensifying in the LVAD space, all eyes are now on recent strategic acquisitions by both companies, as well as ongoing clinical studies and next-generation devices in the pipeline.
CircuLite: Treating Heart Failure’s Lost Patients
Even with all of the advances and options in heart failure therapy, there remain no real options for a large number of patients who are seriously ill but not yet at the end-stage of the disease. CircuLite hopes to change that with a partial support device for patients who don’t need a VAD.